 Todd Bull
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 42 | 2023 | 1794 | 4.260 |
Why?
| | Scleroderma, Systemic | 6 | 2019 | 94 | 1.890 |
Why?
| | Pulmonary Embolism | 5 | 2022 | 183 | 1.420 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 228 | 1.370 |
Why?
| | Vena Cava Filters | 2 | 2020 | 50 | 0.900 |
Why?
| | Thrombolytic Therapy | 3 | 2021 | 117 | 0.850 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 59 | 0.770 |
Why?
| | Airway Obstruction | 1 | 2021 | 168 | 0.710 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 237 | 0.680 |
Why?
| | Familial Primary Pulmonary Hypertension | 12 | 2023 | 193 | 0.670 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 240 | 0.660 |
Why?
| | Thrombosis | 4 | 2023 | 309 | 0.650 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 770 | 0.620 |
Why?
| | Epoprostenol | 4 | 2012 | 132 | 0.600 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 35 | 0.590 |
Why?
| | Vascular Resistance | 5 | 2021 | 356 | 0.570 |
Why?
| | Endovascular Procedures | 1 | 2020 | 275 | 0.560 |
Why?
| | Herpesviridae Infections | 3 | 2008 | 142 | 0.560 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 122 | 0.540 |
Why?
| | Antihypertensive Agents | 2 | 2012 | 438 | 0.540 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1136 | 0.530 |
Why?
| | Exercise Test | 3 | 2023 | 551 | 0.520 |
Why?
| | Altitude Sickness | 1 | 2017 | 163 | 0.520 |
Why?
| | Echocardiography | 2 | 2020 | 556 | 0.490 |
Why?
| | Pulmonary Artery | 9 | 2023 | 1063 | 0.490 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 734 | 0.490 |
Why?
| | Vasodilator Agents | 4 | 2023 | 328 | 0.480 |
Why?
| | Humans | 65 | 2023 | 118983 | 0.470 |
Why?
| | Perioperative Care | 1 | 2014 | 132 | 0.450 |
Why?
| | Altitude | 1 | 2017 | 422 | 0.440 |
Why?
| | Anticoagulants | 5 | 2023 | 559 | 0.430 |
Why?
| | Hypoxia | 5 | 2023 | 963 | 0.430 |
Why?
| | Endothelial Cells | 5 | 2011 | 732 | 0.420 |
Why?
| | Sulfones | 1 | 2012 | 98 | 0.410 |
Why?
| | Blood Cells | 1 | 2010 | 39 | 0.380 |
Why?
| | Venous Thromboembolism | 3 | 2021 | 234 | 0.380 |
Why?
| | Hypertension, Portal | 2 | 2020 | 67 | 0.360 |
Why?
| | Herpesvirus 8, Human | 3 | 2008 | 68 | 0.360 |
Why?
| | Piperazines | 1 | 2012 | 316 | 0.360 |
Why?
| | Oxygen Consumption | 1 | 2012 | 586 | 0.350 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 73 | 0.340 |
Why?
| | Blood Coagulation | 2 | 2021 | 219 | 0.340 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 287 | 0.340 |
Why?
| | Virus Diseases | 1 | 2011 | 198 | 0.330 |
Why?
| | Lung | 8 | 2022 | 3664 | 0.310 |
Why?
| | Time Factors | 2 | 2017 | 6414 | 0.290 |
Why?
| | Acute Lung Injury | 1 | 2010 | 310 | 0.290 |
Why?
| | Blood Vessels | 1 | 2008 | 187 | 0.290 |
Why?
| | Middle Aged | 18 | 2022 | 27623 | 0.280 |
Why?
| | Respiratory Function Tests | 1 | 2007 | 526 | 0.270 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2005 | 8 | 0.270 |
Why?
| | Microarray Analysis | 1 | 2005 | 124 | 0.270 |
Why?
| | Ventricular Function, Right | 4 | 2023 | 257 | 0.270 |
Why?
| | Male | 25 | 2022 | 57808 | 0.260 |
Why?
| | Cardiac Catheterization | 5 | 2023 | 541 | 0.250 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2007 | 457 | 0.250 |
Why?
| | Female | 24 | 2022 | 61574 | 0.240 |
Why?
| | Castleman Disease | 1 | 2003 | 14 | 0.240 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 327 | 0.230 |
Why?
| | Heart Ventricles | 4 | 2023 | 727 | 0.230 |
Why?
| | Gene Expression Profiling | 2 | 2007 | 1597 | 0.220 |
Why?
| | Heparin | 2 | 2021 | 230 | 0.210 |
Why?
| | Vascular Neoplasms | 1 | 2022 | 16 | 0.210 |
Why?
| | Biopsy | 1 | 2005 | 1079 | 0.210 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 16 | 0.200 |
Why?
| | Embolectomy | 1 | 2020 | 10 | 0.190 |
Why?
| | Aromatase | 1 | 2020 | 31 | 0.190 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2020 | 2 | 0.190 |
Why?
| | Tuberculosis | 1 | 2003 | 240 | 0.180 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 26 | 0.180 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 520 | 0.180 |
Why?
| | Thrombectomy | 1 | 2020 | 59 | 0.180 |
Why?
| | Pulmonary Circulation | 4 | 2023 | 424 | 0.180 |
Why?
| | Drug Resistance | 1 | 2020 | 167 | 0.180 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 137 | 0.180 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 230 | 0.180 |
Why?
| | Endothelium, Vascular | 5 | 2007 | 907 | 0.170 |
Why?
| | Risk Factors | 7 | 2018 | 9001 | 0.170 |
Why?
| | Vascular Stiffness | 1 | 2023 | 425 | 0.160 |
Why?
| | Critical Illness | 2 | 2021 | 663 | 0.160 |
Why?
| | Sildenafil Citrate | 2 | 2023 | 57 | 0.160 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1012 | 0.160 |
Why?
| | Aged | 10 | 2021 | 19657 | 0.160 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 290 | 0.160 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2018 | 65 | 0.160 |
Why?
| | Hemodynamics | 2 | 2014 | 1004 | 0.160 |
Why?
| | Estrogens | 1 | 2020 | 329 | 0.160 |
Why?
| | Acute Disease | 1 | 2020 | 941 | 0.150 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 22 | 0.150 |
Why?
| | Schistosoma | 1 | 2017 | 18 | 0.150 |
Why?
| | Purines | 2 | 2023 | 161 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.150 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2021 | 106 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 462 | 0.140 |
Why?
| | Risk Assessment | 3 | 2023 | 3057 | 0.140 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2016 | 38 | 0.140 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 273 | 0.140 |
Why?
| | Pandemics | 2 | 2021 | 1354 | 0.140 |
Why?
| | Adult | 14 | 2023 | 31515 | 0.140 |
Why?
| | Intensive Care Units | 1 | 2020 | 635 | 0.140 |
Why?
| | Retrospective Studies | 8 | 2023 | 12977 | 0.140 |
Why?
| | Patient Care Team | 1 | 2020 | 521 | 0.140 |
Why?
| | Systole | 1 | 2016 | 168 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 968 | 0.130 |
Why?
| | Cohort Studies | 3 | 2017 | 5115 | 0.130 |
Why?
| | Prognosis | 3 | 2013 | 3443 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
| | Health Surveys | 1 | 2017 | 454 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 2 | 2013 | 464 | 0.120 |
Why?
| | Myocardial Contraction | 1 | 2016 | 339 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2011 | 79 | 0.120 |
Why?
| | ROC Curve | 1 | 2016 | 473 | 0.120 |
Why?
| | Heart Failure | 2 | 2020 | 1968 | 0.120 |
Why?
| | Exercise | 3 | 2022 | 1657 | 0.120 |
Why?
| | Blood Pressure | 2 | 2016 | 1664 | 0.120 |
Why?
| | Anesthetics | 1 | 2014 | 58 | 0.120 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 70 | 0.120 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 485 | 0.120 |
Why?
| | Precision Medicine | 1 | 2017 | 363 | 0.110 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 509 | 0.110 |
Why?
| | Drug Discovery | 1 | 2013 | 124 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4596 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1440 | 0.110 |
Why?
| | Drug Storage | 1 | 2012 | 59 | 0.110 |
Why?
| | Phenotype | 3 | 2010 | 3004 | 0.110 |
Why?
| | Drug Stability | 1 | 2012 | 153 | 0.110 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 26 | 0.100 |
Why?
| | Drug Approval | 1 | 2012 | 77 | 0.100 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2011 | 11 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2010 | 2874 | 0.100 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 30 | 0.100 |
Why?
| | Blood Gas Analysis | 1 | 2011 | 69 | 0.100 |
Why?
| | Troponin | 1 | 2011 | 47 | 0.100 |
Why?
| | Europe | 1 | 2012 | 356 | 0.100 |
Why?
| | Case-Control Studies | 4 | 2020 | 3171 | 0.100 |
Why?
| | Antithrombins | 1 | 2011 | 51 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3174 | 0.100 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 70 | 0.100 |
Why?
| | Hyponatremia | 1 | 2011 | 42 | 0.100 |
Why?
| | Medical History Taking | 1 | 2011 | 120 | 0.100 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 26 | 0.100 |
Why?
| | Ultrasonography | 2 | 2011 | 716 | 0.090 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 1868 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2021 | 9343 | 0.090 |
Why?
| | Registries | 3 | 2022 | 1810 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2011 | 300 | 0.090 |
Why?
| | Demography | 1 | 2010 | 274 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 306 | 0.090 |
Why?
| | Aldosterone | 1 | 2009 | 43 | 0.090 |
Why?
| | Cluster Analysis | 1 | 2010 | 481 | 0.080 |
Why?
| | Prospective Studies | 4 | 2022 | 6473 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2220 | 0.080 |
Why?
| | Vasopressins | 1 | 2009 | 64 | 0.080 |
Why?
| | Caspase 7 | 1 | 2008 | 23 | 0.080 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 122 | 0.080 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 34 | 0.080 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 124 | 0.080 |
Why?
| | Electrocardiography | 1 | 2011 | 556 | 0.080 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 112 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 982 | 0.080 |
Why?
| | United States | 4 | 2022 | 12554 | 0.080 |
Why?
| | Research Design | 1 | 2013 | 969 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 410 | 0.080 |
Why?
| | Caspase 3 | 1 | 2008 | 243 | 0.080 |
Why?
| | Animals | 9 | 2017 | 33390 | 0.080 |
Why?
| | Acrolein | 1 | 2007 | 24 | 0.070 |
Why?
| | Colorado | 1 | 2017 | 4196 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2010 | 1085 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1267 | 0.070 |
Why?
| | Quality of Life | 3 | 2022 | 2366 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1474 | 0.070 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2007 | 146 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 827 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2005 | 59 | 0.070 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2005 | 24 | 0.070 |
Why?
| | Pleural Diseases | 1 | 2005 | 21 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 111 | 0.070 |
Why?
| | Comorbidity | 1 | 2010 | 1526 | 0.070 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 86 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 985 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2008 | 688 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4080 | 0.060 |
Why?
| | Biomarkers | 4 | 2013 | 3588 | 0.060 |
Why?
| | Adolescent | 4 | 2021 | 18479 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2008 | 726 | 0.060 |
Why?
| | Algorithms | 1 | 2011 | 1541 | 0.060 |
Why?
| | Vasodilation | 3 | 2010 | 457 | 0.060 |
Why?
| | Blood Circulation | 1 | 2003 | 36 | 0.060 |
Why?
| | Cattle | 2 | 2017 | 979 | 0.060 |
Why?
| | CD36 Antigens | 1 | 2003 | 42 | 0.060 |
Why?
| | E-Selectin | 1 | 2003 | 52 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 544 | 0.060 |
Why?
| | Forecasting | 1 | 2005 | 353 | 0.060 |
Why?
| | Apoptosis | 3 | 2008 | 2484 | 0.060 |
Why?
| | Veins | 1 | 2003 | 60 | 0.060 |
Why?
| | Blood | 1 | 2003 | 100 | 0.060 |
Why?
| | Blood Donors | 1 | 2004 | 109 | 0.060 |
Why?
| | Immunophenotyping | 1 | 2003 | 278 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2016 | 3730 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 384 | 0.050 |
Why?
| | Drainage | 1 | 2003 | 157 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 965 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 50 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 55 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 122 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2005 | 241 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 52 | 0.050 |
Why?
| | Rivaroxaban | 1 | 2023 | 208 | 0.050 |
Why?
| | Vascular Remodeling | 1 | 2023 | 152 | 0.050 |
Why?
| | Proteomics | 2 | 2022 | 876 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 200 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4552 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1158 | 0.050 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2020 | 6 | 0.050 |
Why?
| | Catheters | 1 | 2021 | 61 | 0.050 |
Why?
| | Brachial Artery | 2 | 1999 | 181 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2003 | 455 | 0.050 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 58 | 0.050 |
Why?
| | Mass Screening | 1 | 2007 | 1052 | 0.050 |
Why?
| | United Kingdom | 1 | 2021 | 236 | 0.050 |
Why?
| | Social Determinants of Health | 1 | 2022 | 129 | 0.050 |
Why?
| | Liver Function Tests | 1 | 2020 | 107 | 0.050 |
Why?
| | Outpatients | 1 | 2023 | 325 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2002 | 229 | 0.050 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 126 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1487 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 187 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1691 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 623 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1125 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2446 | 0.040 |
Why?
| | Enalapril | 1 | 1998 | 18 | 0.040 |
Why?
| | Survival Rate | 1 | 2022 | 1720 | 0.040 |
Why?
| | Antigens, Ly | 1 | 2017 | 45 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 300 | 0.040 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2010 | 48 | 0.040 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 101 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 195 | 0.040 |
Why?
| | Education | 1 | 2017 | 105 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2021 | 702 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 687 | 0.040 |
Why?
| | Th2 Cells | 1 | 2017 | 164 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 4713 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2275 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 219 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 443 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 513 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 1784 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2016 | 806 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Mice | 2 | 2007 | 15520 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2436 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 683 | 0.030 |
Why?
| | Perioperative Period | 1 | 2012 | 51 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2020 | 847 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2062 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2013 | 131 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 23 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2011 | 54 | 0.030 |
Why?
| | International Cooperation | 1 | 2012 | 177 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2018 | 6561 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 124 | 0.030 |
Why?
| | Inflammation | 1 | 2022 | 2566 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 219 | 0.020 |
Why?
| | Introns | 1 | 2011 | 234 | 0.020 |
Why?
| | Anesthesia | 1 | 2012 | 120 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 164 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2011 | 147 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2013 | 263 | 0.020 |
Why?
| | Physical Examination | 1 | 2012 | 243 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 243 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 238 | 0.020 |
Why?
| | Leg | 1 | 2011 | 234 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2657 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 34 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 46 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 373 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1224 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 642 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 154 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2010 | 168 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 4908 | 0.020 |
Why?
| | Protein Binding | 1 | 2011 | 1975 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 10795 | 0.020 |
Why?
| | Research | 1 | 2009 | 411 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1346 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 356 | 0.020 |
Why?
| | Gene Expression | 1 | 2010 | 1491 | 0.020 |
Why?
| | Pilot Projects | 1 | 2009 | 1419 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2010 | 892 | 0.020 |
Why?
| | Cell Count | 1 | 2005 | 315 | 0.020 |
Why?
| | Mutation | 2 | 2005 | 3457 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1570 | 0.010 |
Why?
| | Genes, Viral | 1 | 2003 | 93 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 82 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2490 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 67 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 103 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1998 | 3361 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 359 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2235 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2025 | 0.010 |
Why?
| | DNA, Viral | 1 | 2003 | 356 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 296 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 4708 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 420 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 755 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 5692 | 0.010 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 1999 | 6 | 0.010 |
Why?
| | Administration, Sublingual | 1 | 1999 | 14 | 0.010 |
Why?
| | Nitroglycerin | 1 | 1999 | 24 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2002 | 527 | 0.010 |
Why?
| | Lipoprotein(a) | 1 | 1999 | 49 | 0.010 |
Why?
| | Video Recording | 1 | 1999 | 156 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1999 | 199 | 0.010 |
Why?
| | Fibrinogen | 1 | 1999 | 161 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1998 | 88 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 327 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 775 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 1998 | 261 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 984 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1998 | 1687 | 0.010 |
Why?
| | Military Personnel | 1 | 1999 | 529 | 0.010 |
Why?
|
|
Bull's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|